EUCTR2006-006146-34-DE进行中（未招募）不适用
Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial - AIT-CMV-Stage-01
Stage Pharmaceuticals GmbH0 个研究点目标入组 30 人开始时间: 2007年3月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- patient planned for or after allogeneic bone marrow or peripheral blood stem cell transplantation with a chronic persistent CMV infection refractory to antiviral chemotherapy
- •- healthy CMV-seropositive donor who had donated the stem cells in the first place and who will also be considered to donate the CMV-specific lymphocytes
- •- matched unrelated donor (third party donor) if donor who had donated stem cells is CMV seronegative
- •- Streptamer reagents for HLA-typ of patient available
- •- donor and patient agreed to participate in the trial
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- immunosuppressive treatment with > 1mg/kg prednisolon
- •- acute graft versus host disease grade III or IV at time point of transfer
- •- missing written consent of donor and/or patient
- •- diseases affecting the haelth of donor or patient
研究者
相似试验
招募中
1 期
Adoptive immune therapy of chemotherapy-refractory CMV-infection with Streptamer-selected T-cells after allogeneic bone marrow- or peripheral blood stem cell transplantatioB25.9Cytomegaloviral disease, unspecifiedDRKS00000205Stage Pharmaceuticals GmbH30
尚未招募
2 期
In patients with the cancer called Hodgkins lymphoma we are trying to see whether adding a medicine stimulating the immune system will increase the benefit of usual treatmentCTRI/2023/11/060108Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER
招募中
2 期
CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT studybladder/upper urinary tract/urethra cancerUrothelial cancer10038364NL-OMON53642Erasmus MC, Universitair Medisch Centrum Rotterdam58
招募中
1 期
CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT studyrothelial cancer of the bladder, upper urinary tract or urethra.MedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864EUCTR2022-000514-33-NLErasmus MC58
已完成
1 期
T-cell Therapy for CMV (Cytomegalovirus) DiseaseCMV diseaseInfection - Other infectious diseasesACTRN12609000531213Queensland Institute of Medical Research30